Abstract 1041P
Background
Agonistic CD40 antibodies have been shown to promote anti-tumour T cell responses and promising activity has been observed in advanced solid tumours. Here we report the results of a multicenter, open-label study of YH003 + Toripalimab in dose escalation for pts with advanced solid tumours.
Methods
This was a phase I dose-escalation and expansion study. Part 1 was dose-escalation stage using an accelerated “3+3” design. The primary objective of Part 1 was safety and tolerability and to identify a maximum tolerated dose (MTD). Patients with advanced solid tumours received YH003 by IV administration Q3W as monotherapy at 0.03, 0.1, 0.3, 1.0 and 3.0 mg/kg for the first cycle (21 days), then in combination with fixed-dose Toripalimab at 240 mg Q3W from cycle 2. Patients tolerating treatment and deriving benefit could continue treatment for up to 1 year.
Results
Between 29 Jul 2020 and 26 May 2022, 20 pts were treated in Part 1. A DLT (dose-limiting toxicity) was observed at 1.0 mg/kg dose level (grade 3 transaminitis) in 1 pt. The MTD was not reached. Among Part 1 pts, 13 (65%) had any grade treatment related adverse events (TRAEs). The most common (≥ 10%) TRAEs were infusion related reactions, pyrexia, fatigue, nausea, elevated AST/ALT. No Grade 3-5 TRAEs and treatment-related SAEs occurred. 8 pts had received prior immunotherapy (PD-1/PD-L1 or PD-1+CTLA-4). Among 16 pts assessable for response, 1 pt achieved a complete response (CR), another pt achieved a partial response (PR) and 3 pts achieved stable disease (SD). A pt with anti-PD1/anti-CTLA4 refractory ocular melanoma with liver metastases (0.1 mg/kg dose level) achieved PR at the first tumour assessment in week 10 and ultimately a CR after nearly 2 years of study treatment. YH003 was well tolerated up to 3.0 mg/kg dose levels when combined with Toripalimab. Combining safety and preliminary efficacy data, the recommended dose of YH003 for part 2 was 0.3 mg/kg.
Conclusions
YH003 was well tolerated up to 3.0 mg/kg dose levels when combined with Toripalimab, and 0.3mg/kg was deemed the RP2D. YH003 has shown encouraging antitumour activity in patients with advanced solid tumours.
Clinical trial identification
NCT04481009.
Editorial acknowledgement
Legal entity responsible for the study
Eucure (Beijing) Biopharma Co., Ltd.
Funding
Eucure (Beijing) Biopharma Co., Ltd.
Disclosure
B. Markman: Financial Interests, Personal, Advisory Board: Amgen, MSD, Bristol Myers Squibb, BeiGene, AstraZeneca. J. Coward: Financial Interests, Institutional, Research Funding: AstraZeneca. M. Millward: Financial Interests, Personal, Advisory Board: BeiGene Australia Pty Ltd, Bristol Myers Squibb Australia Pty Ltd, AstraZeneca Australia Pty Ltd, The Limbic, Eli Lilly Australia Pty Ltd, IQVIA Australia Pty Ltd, Amgen Australia Pty Ltd, Merck Pte Ltd, Pfizer Australia Pty Ltd, Guardant Health, Roche Products Pty Ltd; Financial Interests, Personal, Full or part-time Employment, Employee: University of Western Australia; Financial Interests, Personal, Other, Consultant: Linear Clinical Research; Financial Interests, Institutional, Local PI, Trial payments to Institution: Bristol Myers Squibb, Genentech/Roche, BeiGene, Eli Lilly, Albion Laboratories, Akeso Biopharma, AbbVie, Five Prime Therapeutics, Dizal Pharma, Maxinovel, Amgen, Atridia, INXMED, Alpine Immune Sciences, Turning Point Therapeutics, IMPACT Therapeutics, Kinnate Biopharma, Rely Therapeutics, GenFleet Therapeutics, Vivace Therapeutics, Eucure Biopahrma, InventisBio, Cullinan Oncology, Tyra Biosciences, Axelia Oncology; Non-Financial Interests, Other, Scientific Advisory Committee member: Thoracic Oncology Group Australasia. All other authors have declared no conflicts of interest.
Resources from the same session
1353P - Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
Presenter: Jamie Feng
Session: Poster session 19
1354P - Beyond the common mutation: Examining chemotherapy success in uncommon EGFR mutations
Presenter: Chien-Chung Lin
Session: Poster session 19
1355P - Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
Presenter: Marta Brambilla
Session: Poster session 19
1356P - 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
Presenter: Yu Tanaka
Session: Poster session 19
1357P - Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
Presenter: YuanLiang Zhou
Session: Poster session 19
1358P - Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Presenter: Ernest Nadal
Session: Poster session 19
1359P - Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Presenter: Marc Denis
Session: Poster session 19
1361P - Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Presenter: Shirish Gadgeel
Session: Poster session 19
1362P - Association of baseline (BL) anaplastic lymphoma kinase (ALK) fusion detected by circulating tumor DNA (ctDNA) with clinical features and outcomes in the phase III ALTA-3 trial
Presenter: Charu Aggarwal
Session: Poster session 19